Volume 16, Number 3—March 2010
Dispatch
Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs
Table
Strains | Passage history | NA mutation | IC50s of NA inhibitors |
Amantadine sensitivity† (M2 mutation) | |||
---|---|---|---|---|---|---|---|
Zanamivir, nM ± SD | Fold change | Oseltamivir, nM ± SD | Fold change | ||||
All NAI-sensitive subtype H3N2 isolates‡ | MDCK2 | None | 1.12 ± 0.40 | 1 | 0.86 ± 0.44 | 1 | Resistant (S31N) |
A/Myanmar/M187/2007 | MDCK2 | Q136K | 59.72 ± 3.83 | 53.3 | 0.13 ± 0.05 | 0.2 | Resistant (S31N) |
A/Myanmar/M114/2008 | MDCK2 | Q136K | 33.37 ± 7.02 | 29.8 | 0.16 ± 0.03 | 0.2 | Resistant (S31N) |
A/Texas/131/2002§ | None | 1.43 ± 0.09 | 1.3 | 0.99 ± 0.09 | 1.2 | Sensitive | |
A/Texas/131/2002_E119V§ | E119V | 5.43 ± 0.68 | 4.8 | 94.33 ± 2.06 | 109.7 | Sensitive |
*NA, neuraminidase;IC50, inhibitory concentration; NAI, neuraminidase inhibitors.
†Amantadine sensitivity was based on M2 genotyping data.
‡Average IC50 was calculated excluding the control viruses (n = 47).
§Reference strains used as drug-sensitive and -resistant control viruses in the NAI assay.
Page created: December 14, 2010
Page updated: December 14, 2010
Page reviewed: December 14, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.